Diary No. 5238 dated 25.04.19

F. No. 12-03/19-DC
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

Tele No.011-23236965
Fax.No.011-23236973

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated 25 NOV 2019

To
Director,
National Institute of Tuberculosis and Respiratory Diseases,
Sri Aurobindo Marg, New Delhi - 110 030.

Subject:- Permission for conducting clinical study entitled, "Two-month regimens using Novel combinations to Augment Treatment effectiveness for drug-sensitive tuberculosis" - regarding.

Sir,

With reference to your application dated 24.04.2019, please find enclosed herewith the permission in Form CT-06, No. **CT/ND/102/2019** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019.**

This permission is subject to the conditions, as mentioned below.

Yours faithfully

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

Condition of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of

receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits Director, National Institute of Tuberculosis and Respiratory Diseases, Sri Aurobindo Marg, New Delhi - 110 030, India to conduct clinical trial of the investigational new drug as per **Protocol - TRUNCATE-TB, Version No. 1.2, Dated 08.08.2016** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	Rifampicin, Isoniazid, Pyrazinamide, Ethambutol, Levofloxacin, Clofazimine, Bedaquiline, Linezolid, Rifapentine, Pyridoxine.
Therapeutic class:	Details annexed as **Annexure A.**
Dosage form:	Details annexed as **Annexure B.**
Composition:	Details annexed as **Annexure C.**
Indications	As already approved.

Details of clinical trial sites-

Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
01	**Dr. Rohit Sarin,** National Institute of Tuberculosis and Respiratory Diseases, Sri Aurobindo Marg, New Delhi - 110 030.	Ethics Committee, National Institute of TB and Respiratory Diseases, Sri Aurobindo Marg, Near Qutub Minar, New Delhi - 110 030. India. **ECR/315/Inst/DL/2013/RR-16**
02	**Dr. Syed Hissar,** National Institute of Research in Tuberculosis, No. 1, Mayor Sathyamoorthy Road, Chetput, Chennai - 600 031.	Institutional Ethics Committee, National Institute for Research in Tuberculosis (ICMR), No. 1, Mayor Sathyamoorthy Road, Chetput, Chennai - 600 031. **ECR/135/Inst/TN/2013/RR-16**
03	**Dr. Rajesh Solanki,** B. J. Medical College and Hospital, Ahmedabad - 380 016.	Institutional Ethics Committee, B. J. Medical College and Civil Hospital, Office of Medical Superintendent, Ahmedabad - 380 016. **ECR/72/Inst/GJ/2013/RR-16**

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

(Dr. V. G. Somani)
Central Licensing Authority

Stamp

New Delhi
Date 25 NOV 2019

Annexure A

Drugs	Therapeutic Class
Rifampicin	Anti Tuberculosis
Isoniazid	Anti Tuberculosis
Pyrazinamide	Anti Tuberculosis
Ethambutol	Anti Tuberculosis
Levofloxacin	Antibiotic
Clofazimine	Anti Tuberculosis
Bedaquiline	Anti Tuberculosis
Linezolid	Antibiotic
Rifapentine	Anti Tuberculosis
Pyridoxine	Vitamin

Annexure B

Dosage Form:-

1. Fixed dose combination tablets containing rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg, ethambutol 275 mg.
2. Fixed dose combination tablets containing rifampicin 150 mg, isoniazid 75 mg, ethambutol 275mg.
3. Rifampicin 300 mg capsules.
4. Rifampicin 150 mg capsules.
5. Isoniazid 300 mg tablets.
6. Isoniazid 100 mg tablets.
7. Pyrazinamide 500 mg tablets.
8. Ethambutol 400 mg tablets.
9. Ethambutol 100 mg tablets.
10. Linezolid 600 mg tablets
11. Clofazimine 100 mg capsules
12. Rifapentine 150 mg tablets.
13. Levofloxacin 500 mg tablets
14. Bedaquiline 100 mg tablets
15. Pyridoxine 10 mg tablets

Annexure C

Drugs	Composition
Fixed dose combination tablets containing rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg, ethambutol 275 mg	Rifampicin 150 mg, Ethambutol hydrochloride 275 mg, Isoniazid 75 mg, Pyrazinamide 400 mg
Fixed dose combination tablets containing rifampicin 150 mg, isoniazid 75 mg, ethambutol 275mg	Ethambutol hydrochloride 275 mg, Isoniazid 75 mg, Rifampicin 150 mg
Rifampicin 300 mg capsules	Rifampicin 300 mg, 0.7 mg of carmoisine (azorubine), 0.1728 mg of sodium methyl parahydroxybenzoate, 0.0192 mg of sodium propyl parahydroxybenzoate, 0.28 mg of sunset yellow (FD&C yellow #6), 0.196 mg ponceau 4R (cochineal red A)
Rifampicin 150 mg capsules	Rifampicin 150 mg, 0.168 mg of FD&C Yellow #6 / Sunset Yellow, 0.3173 mg of carmoisine, 0.0933 mg of Ponceau 4R, 0.1728 mg of sodium methylparaben, 0.0192 propylparaben
Isoniazid 300 mg tablets	Isoniazid 300 mg
Isoniazid 100 mg tablets	Isoniazid 100 mg
Pyrazinamide 500 mg tablets	Pyrazinamide 500 mg
Ethambutol 400 mg tablets	Ethambutol Hydrochloride BP 400 mg
Ethambutol 100 mg tablets	Ethambutol hydrochloride 100 mg
Linezolid 600 mg tablets	Linezolid 600 mg
Clofazimine 100 mg capsules	Micronized clofazimine suspended in an oil-wax base 100 mg
Rifapentine 150 mg tablets	Rifapentine150 mg
Levofloxacin 500 mg tablets	Levofloxacin (as hemihydrate) 500 mg
Bedaquiline 100 mg	Bedaquiline fumarate equivalent to 100 mg of bedaquiline, 145 mg of lactose (as monohydrate)
Pyridoxine 10 mg tablets	Pyridoxine 10 mg